Cabometyx EU

Cabometyx in Europe

Contact
This is a promotional website intended for Healthcare Professionals in EU, excluding France
Abbreviations
Safety Information
SmPC

Select an indication for CABOMETYX® (cabozantinib)

CABOMETYX® is a small molecule that inhibits multiple receptor tyrosine kinases implicated in tumour growth and angiogenesis, pathologic bone remodelling, drug resistance and metastatic progression of cancer.1 Please select an indication to find out more.

Renal Cell Carcinoma

CABOMETYX® (cabozantinib) for the treatment of advanced renal cell carcinoma:1

• In treatment-naïve adults with intermediate or poor risk

• In adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

Hepatocellular Carcinoma

CABOMETYX® (cabozantinib) for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.1

1. CABOMETYX® Summary of Product Characteristics. View the CABOMETYX®SmPC

© Ipsen Group 2019 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the EU – excluding France. Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Welcome to Cabometyx.eu website. This website is intended for EU Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.

 

I AM A EU HEALTHCARE PROFESSIONAL

I AM A FRENCH HEALTHCARE PROFESSIONAL

I AM NOT A EU HEALTHCARE PROFESSIONAL

Learn more

*ln a Phase 3, randomised, open-label study comparing CABOMETYX® (n=330) with everolimus (n=328) in adult patients with aRCC progressing alter prior anti-VEGF therapy.1
2L: Second-Line, Cl: Confidence lnterval, HR: Hazard Ratio, IMDC: International Metastatic Renal Cell Carcinoma Database, OS: Overall Survival, TKI: Tyrosine Kinase lnhibitor.
CABOMETYX® is indicated for the treatment of advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk per IMDC criteria and in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.2
References: 1. Motzer RJ, et al. Br J Cancer. 2018; 118(9): 1176-8. 2. CABOMETYX® Summary of Product Characteristics. 3. Choueiri TK, et al. Lancet Oncol. 2016; 17(7): 917-27. 4. Choueiri TK, et al. Eur J Cancer. 2018; 94: 115-25. 5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 4.2019 - April 2019. 6. Escudier B, et al. Ann Oncol. 2019; 30(5): 706-20. 7. European MedicinesAgency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: cabozantinib, 2018. Available from: www.ema.europa Accessed April 2019.
© lpsen Group 2019 Last updated on: February 2020. This site is published by lpsen, which is solely responsible for the content. It is intended only for healthcare professionals from the EU - excluding France. Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001951